7-Ethoxycoumarin rescued Caenorhabditis elegans from infection of COPD derived clinical isolate Pseudomonas aeruginosa through virulence and biofilm inhibition via targeting Rhl and Pqs quorum sensing systems

Bajire, Sukesh Kumar; Prabhu, Ashwini; Bhandary, Yashodhar P.; Irfan, K; Shastry, Rajesh P.

doi:10.1007/s11274-023-03655-8

Cited by 3 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulmonary nocardiosis [38] Bacteria G − Pseudomonas aeruginosa CF, COPD [39,40] Escherichia coli VAP [41]…”

Section: Nocardiamentioning

confidence: 99%

Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections

Guo,

Mao,

Ran

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Airway mucus dysfunction and impaired immunological defenses are hallmarks of several lung diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary diseases, and are mostly causative factors in bacterial-biofilm-associated respiratory tract infections. Bacteria residing within the biofilm architecture pose a complex challenge in clinical settings due to their increased tolerance to currently available antibiotics and host immune responses, resulting in chronic infections with high recalcitrance and high rates of morbidity and mortality. To address these unmet clinical needs, potential anti-biofilm therapeutic strategies are being developed to effectively control bacterial biofilm. This review focuses on recent advances in the development and application of nanoparticulate drug delivery systems for the treatment of biofilm-associated respiratory tract infections, especially addressing the respiratory barriers of concern for biofilm accessibility and the various types of nanoparticles used to combat biofilms. Understanding the obstacles facing pulmonary drug delivery to bacterial biofilms and nanoparticle-based approaches to combatting biofilm may encourage researchers to explore promising treatment modalities for bacterial-biofilm-associated chronic lung infections.

show abstract

“…Pulmonary nocardiosis [38] Bacteria G − Pseudomonas aeruginosa CF, COPD [39,40] Escherichia coli VAP [41]…”

Section: Nocardiamentioning

confidence: 99%

Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections

Guo,

Mao,

Ran

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

3-(Bromoacetyl) coumarin is a potential therapeutic agent against neonatal sepsis-associated Pseudomonas extremorientalis

Banerjee,

Bajire,

Mithun

et al. 2023

Arch Microbiol

View full text Add to dashboard Cite

Loop-mediated isothermal amplification (LAMP) assay for early on-site detection of Group B Streptococcus infection in neonatal sepsis blood sample

Banerjee,

K.,

Shastry

2024

Mol Biol Rep

View full text Add to dashboard Cite

7-Ethoxycoumarin rescued Caenorhabditis elegans from infection of COPD derived clinical isolate Pseudomonas aeruginosa through virulence and biofilm inhibition via targeting Rhl and Pqs quorum sensing systems

Cited by 3 publications

References 42 publications

Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections

Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections

3-(Bromoacetyl) coumarin is a potential therapeutic agent against neonatal sepsis-associated Pseudomonas extremorientalis

Loop-mediated isothermal amplification (LAMP) assay for early on-site detection of Group B Streptococcus infection in neonatal sepsis blood sample

Contact Info

Product

Resources

About